[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"remote-ischemic-conditioning\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:remote-ischemic-conditioning":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100570936","remote-ischemic-conditioning-for-non-proliferative-diabetic-retinopathy-100570936",false,"NCT06713720","Remote Ischemic Conditioning for Non-Proliferative Diabetic Retinopathy","Remote Ischemic Conditioning for Non-Proliferative Diabetic Retinopathy (RIC-NPDR)","RIC-NPDR","Inclusion Criteria:\n\n* Age between 40 and 80 years.\n* Diagnosed with Type 2 diabetes mellitus.\n* Diagnosed with mild to moderate non-proliferative diabetic retinopathy (NPDR) with a DR Severity Score (DRSS) grade of 20-47D.\n* Capable of performing daily activities independently.\n* Willing and able to provide informed consent.\n\nExclusion Criteria:\n\n* Presence of diabetic macular edema (macular thickness \\> 250 μm).\n* Significant eye diseases affecting evaluation, such as high myopia, severe cataract, corneal leucoma, glaucoma, retinal detachment, retinal vein occlusion, congenital eye diseases, ocular tumors, or severe infection.\n* History of ocular laser or intraocular surgery.\n* Poor imaging quality due to refractive media opacity.\n* Contraindication to fluorescein fundus angiography.\n* Unstable blood glucose (HbA1c ≥ 8.0%) despite oral antidiabetic drugs.\n* Severe diabetes complications within the past 6 months.\n* Severe, sustained hypertension (systolic ≥ 180 mmHg or diastolic ≥ 110 mmHg).\n* Body mass index (BMI) ≥ 28 kg\u002Fm².\n* Hepatic or renal insufficiency: Alanine aminotransferase or aspartate aminotransferase \\> 2 times the upper limit of normal. Estimated glomerular filtration rate (eGFR) \\\u003C 60 mL\u002Fmin\u002F1.73m². Urine albumin\u002Fcreatinine ratio ≥ 30 mg\u002Fg.\n* Myocardial infarction within the past 6 months.\n* Neurological diseases such as Alzheimer's, Parkinson's, cerebrovascular disease, intracranial tumor, cerebrovascular malformation, or aneurysm.\n* Contraindications to RIC, including one-sided subclavian artery stenosis, upper limb injuries or vascular diseases, or limb deformities.\n* Severe systemic diseases, such as malignant tumors with a life expectancy of less than 24 months.\n* Known pregnancy or breastfeeding.\n* Participation in other experimental clinical studies.\n* Any other conditions deemed unsuitable by the investigator.","ALL","40 Years","80 Years",{"count":21,"type":22},68,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to evaluate whether remote ischemic conditioning (RIC) is a safe and effective treatment for non-proliferative diabetic retinopathy (NPDR) in adults aged 40-80 years with type 2 diabetes. The study aims to address the limitations of current treatments for NPDR by using RIC, a technique involving repeated cycles of ischemia and hypoxia stimulation to activate protective mechanisms against retinal damage.\n\nThe main questions it aims to answer are:\n\nDoes RIC improve the Diabetic Retinopathy Severity Score (DRSS) after one year of treatment? Does RIC reduce the incidence of vision-threatening proliferative diabetic retinopathy (PDR)? What are the changes in retinal neurovascular unit parameters, visual acuity, and retinal oxygen saturation after RIC treatment?\n\nParticipants will:\n\nUndergo RIC therapy using a specialized device on both upper limbs (or a placebo intervention for the control group) for 1 year.\n\nComplete 5 cycles of RIC or placebo treatment twice daily, 5 days per week. Receive routine care for diabetic retinopathy as per clinical guidelines.\n\nKey outcome measures:\n\nPrimary outcome: Change in DRSS from baseline after one year. Secondary outcomes: Incidence of PDR, changes in visual acuity, retinal neurovascular unit measures, retinal oxygen saturation, and serum biomarkers (e.g., VEGF, CRP, IL-6).\n\nThis randomized, double-blind, placebo-controlled trial aims to recruit 68 participants to ensure 60 complete the study, accounting for a 13% dropout rate. The findings are expected to provide insights into RIC as a novel intervention for NPDR, reducing blindness risk and supporting future large-scale trials.",[28,29,30,31,32],"Diabetic Retinopathy","Non-Proliferative Diabetic Retinopathy","Remote Ischemic Conditioning","Diabetes Mellitus, Type 2","Randomized Controlled Trial",[29,28,34,30,32],"Retinal Neurovascular Unit","RECRUITING","2025-06-22",{"date":38,"type":39},"2025-06-26","ACTUAL",{"date":41,"type":39},"2025-04-20",{"date":43,"type":22},"2026-05-31",{"name":45,"class":46},"Xuxiang Zhang, MD","OTHER",2,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100586847","efficacy-of-remote-ischemic-conditioning-in-preventing-post-stroke-depression-100586847","NCT06920706","Efficacy of Remote Ischemic Conditioning in Preventing Post-Stroke Depression","Efficacy of Remote Ischemic Conditioning in Preventing Post-Stroke Depression: A Multicenter, Randomized, Double-Blind, Sham-Controlled Clinical Trial","Inclusion Criteria:\n\n* Patient age≥18 years;\n* No gender preference;\n* Diagnosed with acute ischemic stroke;\n* From onset to treatment ≤48 h;\n* 6≤ NIHSS scores ≤25;\n* Premorbid mRS ≤1;\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Baseline HAMD-24 scores ≥8;\n* Infarction area overlapped with the area where the DTI-ALPS index is calculated;\n* A history of severe mental illness such as depression, bipolar disorder, and schizophrenia;\n* A history of mental disorders caused by other organic diseases, such as post-Parkinson depression;\n* Participants with cognitive impairment, disturbance of consciousness, severe hearing impairment, or aphasia who were unable to cooperate with the assessment;\n* A history of autoimmune diseases (such as multiple sclerosis, neuromyelitis optica spectrum disorders, systemic lupus erythematosus, etc.), malignant tumors, or obstructive sleep apnea hypopnea syndrome;\n* Intracranial tumor, arteriovenous malformation, or aneurysm;\n* Uncontrolled severe hypertension (systolic pressure \\>180mmHg or diastolic pressure \\>110 mmHg after drug treatment) ;\n* Subclavian artery stenosis≥50% or subclavian steal syndrome;\n* Any contraindication for remote ischemic adaptation: the upper limb has serious soft tissue injury, fracture or vascular injury, distal upper limb perivascular lesions, etc.;\n* Severe coagulation dysfunction, platelet count \\\u003C 100×10\\^9\u002FL, cardiac dysfunction (NYHA class Ⅲ or above), hepatic dysfunction (aspartate aminotransferase and\u002For alanine aminotransferase \\> 3 times the upper limit of normal), or renal dysfunction (serum creatinine \\> 265μmol\u002FL);\n* Any contraindication for magnetic resonance imaging: metal implants, claustrophobia, etc.;\n* Women known to be pregnant or lactating, or have a positive pregnancy test;\n* Participating in other clinical trials within three months;\n* Participants not suitable for this clinical studies considered by researcher.","18 Years",{"count":57,"type":22},240,[25],"Post-stroke depression (PSD) is characterized primarily by low mood and loss of interest following a stroke. It is one of the most common and serious complications of stroke, with an incidence of 11% to 41% within two years post-stroke. PSD significantly impacts stroke prognosis, not only hindering neurological recovery but also increasing clinical disability and mortality rates, thereby imposing substantial economic and psychological burdens on families and society. Therefore, preventing PSD is crucial for stroke rehabilitation.\n\nClinical trials have demonstrated that preventive antidepressant treatment can reduce PSD incidence and improve clinical outcomes; however, controversies remain regarding the timing, methods, and safety. Meanwhile, preventive psychological therapy faces challenges in implementation due to effectiveness, accessibility, and cost-effectiveness.\n\nRemote ischemic preconditioning (RIC) is a non-invasive, cost-effective, and non-pharmacological intervention. By modulating small molecules in the peripheral and central nervous systems through transient, periodic limb blood flow restriction and reperfusion, RIC reverses neurobiological changes and demonstrates neuroprotective potential in various neurological diseases. Recently, a study showed that RIC is safe and effective in preventing PSD; however, the sample size is small and the specific mechanisms remain unclear. Therefore, this study aims to further explore the role and mechanisms of RIC in PSD prevention.",[61,30],"Post-stroke Depression","NOT_YET_RECRUITING","2025-04-02",{"date":65,"type":39},"2025-04-10",{"date":65,"type":22},{"date":68,"type":22},"2026-12-31",{"name":70,"class":46},"Xuanwu Hospital, Beijing",5,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":97},"100526959","safety-and-efficacy-of-remote-ischemic-conditioning-for-patients-taking-off-pump-coronary-artery-bypass-grafting-100526959","NCT06141525","Safety and Efficacy of Remote Ischemic Conditioning for Patients Taking Off-pump Coronary Artery Bypass Grafting","Safety and Efficacy of Remote Ischemic Conditioning for Patients Taking Off-pump Coronary Artery Bypass Grafting (IMPROVE): A National, Multi-center, Randomized, Controlled, Open-label, Blinded-endpoint Trial","IMPROVE","Inclusion Criteria:\n\n* Diagnosed with coronary artery disease and require off-pump CABG surgery.\n* Between 18 and 75 years old;\n* Normal left ventricular systolic function (ejection fraction \\>40%) and left ventricular end-diastolic internal diameter (\\\u003C60 mm) in the cardiac ultrasound tests;\n* No or mild heart valve and great vessel abnormalities which do not require surgical intervention;\n* Participants or their authorized relatives agree to participate in the clinical trial and sign the informed consent.\n\nExclusion Criteria:\n\n* Severe tissue injuries.\n* Myalgia, fractures and other peripheral vascular lesions.\n* Bypass graft being the radial artery.\n* Stenosis or severe malformations of the subclavian, jugular and femoral arteries and veins.\n* Previous vagus nerve trunk dissection or vagus nerve block surgery.\n* Other surgical operations at the same time.\n* Patients with pre-existing severe cardiac insufficiency, acute coronary syndromes, malignant hypertension and cardiogenic shock.\n* Severe coagulation abnormality or severe anemia.\n* Severe mental disorder.\n* Malignant tumors.\n* Pregnant or lactating.\n* Increased risk of treatment for patients, according to investigators.\n* Refuse to sign the informed consent form.","70 Years",{"count":82,"type":22},648,[25],"Remote ischemic conditioning (RIC) is the process of repeated ischemia and reperfusion in the peripheral vessels, which is proved in reducing IRI in vital organs. This IMPROVE trial plans to enroll 648 patients who are diagnosed with coronary artery disease and are going to take off-pump CABG in five centers in China, to access whether RIC can and improve short-term prognosis.",[86,30,87],"Coronary Artery Bypass Grafting","Ischemia-Reperfusion Injury","2024-07-10",{"date":90,"type":39},"2024-07-12",{"date":92,"type":39},"2023-11-22",{"date":94,"type":22},"2029-03-31",{"name":96,"class":46},"First Affiliated Hospital Xi'an Jiaotong University",1]